These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32416712)

  • 21. Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer.
    Xing L; Shi Q; Zheng K; Shen M; Ma J; Li F; Liu Y; Lin L; Tu W; Duan Y; Du L
    Theranostics; 2016; 6(10):1573-87. PubMed ID: 27446491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use.
    Parashar D; Rajendran V; Shukla R; Sistla R
    Eur J Pharm Sci; 2020 Jan; 142():105159. PubMed ID: 31747618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy.
    Jeong K; Kang CS; Kim Y; Lee YD; Kwon IC; Kim S
    Cancer Lett; 2016 Apr; 374(1):31-43. PubMed ID: 26854717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review.
    Varshosaz J; Taymouri S
    Curr Pharm Des; 2015; 21(29):4310-28. PubMed ID: 26323421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
    Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
    Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of Star Polymer Nanoparticles for the Delivery of siRNA to Mouse Orthotopic Pancreatic Tumor Models.
    McCarroll JA; Sharbeen G; Kavallaris M; Phillips PA
    Methods Mol Biol; 2019; 1974():329-353. PubMed ID: 31099013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
    Zhu L; Zhou Z; Mao H; Yang L
    Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial: Polymeric Nanocarriers as Robust Platforms for Cancer Therapy.
    Elzoghby AO
    Curr Pharm Des; 2017; 23(35):5211-5212. PubMed ID: 29110600
    [No Abstract]   [Full Text] [Related]  

  • 31. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
    Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
    Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CaCO
    Dong Z; Feng L; Zhu W; Sun X; Gao M; Zhao H; Chao Y; Liu Z
    Biomaterials; 2016 Dec; 110():60-70. PubMed ID: 27710833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment.
    Song C; Wang X; Wang Y; Yu H; Cui Y; Ma T
    Curr Drug Metab; 2018; 19(2):131-141. PubMed ID: 28758578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanocarriers: a tool to overcome biological barriers in siRNA delivery.
    Kumari A; Kumar V; Yadav SK
    Expert Opin Biol Ther; 2011 Oct; 11(10):1327-39. PubMed ID: 21682658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
    Taniguchi H; Natori Y; Miyagi Y; Hayashi K; Nagamura F; Kataoka K; Imai K
    Int J Cancer; 2021 Aug; 149(3):646-656. PubMed ID: 33783816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined use of nanocarriers and physical methods for percutaneous penetration enhancement.
    Dragicevic N; Maibach H
    Adv Drug Deliv Rev; 2018 Mar; 127():58-84. PubMed ID: 29425769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.
    Buanes TA
    World J Gastroenterol; 2016 Dec; 22(48):10502-10511. PubMed ID: 28082802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellulose-based Nanocarriers as Platforms for Cancer Therapy.
    Meng LY; Wang B; Ma MG; Zhu JF
    Curr Pharm Des; 2017; 23(35):5292-5300. PubMed ID: 29086678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer.
    Huang J; Qian W; Wang L; Wu H; Zhou H; Wang AY; Chen H; Yang L; Mao H
    Int J Nanomedicine; 2016; 11():3087-99. PubMed ID: 27462153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.